Unknown

Dataset Information

0

B Cell-Based Cancer Immunotherapy.


ABSTRACT: B cells are not only producers of antibodies, but also contribute to immune regulation or act as potent antigen-presenting cells. The potential of B cells for cellular therapy is still largely underestimated, despite their multiple diverse effector functions. The CD40L/CD40 signaling pathway is the most potent activator of antigen presentation capacity in B lymphocytes. CD40-activated B cells are potent antigen-presenting cells that induce specific T-cell responses in vitro and in vivo. In preclinical cancer models in mice and dogs, CD40-activated B cell-based cancer immunotherapy was able to induce effective antitumor immunity. So far, there have been only few early-stage clinical studies involving B cell-based cancer vaccines. These trials indicate that B cell-based immunotherapy is generally safe and associated with little toxicity. Furthermore, these studies suggest that B-cell immunotherapy can elicit antitumor T-cell responses. Alongside the recent advances in cellular therapies in general, major obstacles for generation of good manufacturing practice-manufactured B-cell immunotherapies have been overcome. Thus, a first clinical trial involving CD40-activated B cells might be in reach.

SUBMITTER: Wennhold K 

PROVIDER: S-EPMC6558332 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

B Cell-Based Cancer Immunotherapy.

Wennhold Kerstin K   Shimabukuro-Vornhagen Alexander A   von Bergwelt-Baildon Michael M  

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 20190204 1


B cells are not only producers of antibodies, but also contribute to immune regulation or act as potent antigen-presenting cells. The potential of B cells for cellular therapy is still largely underestimated, despite their multiple diverse effector functions. The CD40L/CD40 signaling pathway is the most potent activator of antigen presentation capacity in B lymphocytes. CD40-activated B cells are potent antigen-presenting cells that induce specific T-cell responses in vitro and in vivo. In precl  ...[more]

Similar Datasets

| S-EPMC6063311 | biostudies-literature
| S-EPMC4509852 | biostudies-literature
| S-EPMC7928408 | biostudies-literature
| S-EPMC9266896 | biostudies-literature
| S-EPMC9323201 | biostudies-literature
| S-EPMC4257036 | biostudies-literature
| S-EPMC7642255 | biostudies-literature
| S-EPMC9255073 | biostudies-literature
| S-EPMC10768003 | biostudies-literature
| S-EPMC10142387 | biostudies-literature